News

Sarepta's Setback Deepens With Another Gene Therapy Fatality
Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...
Sarepta shares slump after third patient death this year
By Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental gene therapy died, deepening investor concerns ...
STAT7m
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
Stocktwits on MSN47m
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Shares of Sarepta Therapeutics (SRPT) tumbled 14% on Friday after a patient reportedly died following treatment with one of the firm’s gene therapies, drawing concerns from Wall Street analysts. A ...
Precision Medicine Online7m
Sarepta Shares Drop on Reports of Patient Death in Gene Therapy Trial
A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.